within Pharmacolibrary.Drugs.N_NervousSystem.N06B_PsychostimulantsAgentsUsedForAdhdAndNootropics.N06BA02_Dexamfetamine;

model Dexamfetamine
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.75,
    Cl = 2.5277777777777778e-06,
    adminDuration = 600,
    adminMass = 10 / 1000000,
    adminCount = 1,
    Vd = 0.00544,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0061333333333333335,
    Tlag = 1800);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Dexamfetamine</td></tr><tr><td>ATC code:</td><td>N06BA02</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>10</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>5.44</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.13</td><td>L/h/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Dexamfetamine (also known as dextroamphetamine) is a central nervous system stimulant of the phenethylamine class. It is used for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy, and is approved for these indications in numerous countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult subjects (both sexes) after a single oral dose.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N06BA02 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Dexamfetamine;
